Search Results
Your search for ,maY matches 17173 pages
Showing 3851 - 3900Downstaging Hepatocellular Carcinoma Prior to Liver Transplant: 10-Year Outcomes
In some patients with hepatocellular carcinoma, downstaging of disease to within criteria that qualify the patient for a liver transplant leads to excellent 10-year posttransplant outcomes, according to new research published by Tabrizian et al in JAMA Surgery. The results validate current national ...
AMA House of Delegates Approves ASCO-Backed Resolutions on Ancillary Clinical Trial Costs and ARPA-H Funding
From June 10 to 15, delegates from the Association for Clinical Oncology (ASCO) participated in the 2022 Annual Meeting of the American Medical Association’s (AMA) House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and...
ASCO Guideline Update Supports New Second- and Third-Line Treatments for HER2-Positive Breast Cancer
ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer, just 4 years after the previous practice guideline update was released in 2018.1,2 This latest update reviews results from multiple clinical trials published between 2016 and 2021 that...
CAR T-Cell Reimbursement, Measuring Health Disparities, Digital Quality in Focus in Comments on 2023 Hospital Inpatient Payment Proposal
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the fiscal year (FY) 2023 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Prospective Payment System (PPS) proposed rule. ASCO’s comments address...
Study Finds Radiation Therapy May Be Safely Omitted for Some Older Patients With Luminal A Breast Cancer
For some patients aged 55 or older with early-stage, low-risk breast cancer, endocrine therapy following breast-conserving surgery may be sufficient without the need for postoperative radiation therapy, according to the results of the prospective LUMINA trial, reported at the 2022 ASCO Annual...
Medical Costs and Clinical Value: Playing the Long Game
Even as soaring medical costs strain public and private budgets around the world, patients yearn for therapeutic breakthroughs. Game-changing cancer treatments, emerging antiviral agents, and mRNA vaccines are powerful reminders of medical technology’s potential. But insurance premiums and...
Changing the Natural History of ER-Positive, HER2-Negative Breast Cancer With the Introduction of CDK4/6 Inhibition
It has been 14 years since a collaboration between the University of California, Los Angeles (UCLA) and Pfizer identified a unique role for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in estrogen receptor (ER)-positive human cell line models and demonstrated that these agents act...
Adherence to VTE Prophylaxis Guidelines After Pancreatic Cancer Surgery
In a U.S. retrospective cohort study reported in JAMA Surgery, Perry et al found that a very small percentage of patients filled prescriptions for guideline-recommended venous thromboembolism (VTE) prophylaxis after undergoing surgery for pancreatic cancer. As stated by the investigators, “VTE is...
Researchers Discover Protein That May Be Associated With Better Prognosis for Patients With Ovarian Cancer
Researchers have discovered that a protein associated with metabolism—and formerly recognized as a potential therapeutic target for ovarian cancer—may instead be associated with a better prognosis for patients with the malignancy. In a report published by Clemente et al in Cancer Research...
Survey Finds More Than 80% of Patients With Cancer and Survivors Say Copay Assistance Programs Help Them Afford Their Prescription Drugs
A new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN) showed that a majority of respondents (83%) who had applied to a copay assistance program and were accepted said the assistance enables them to get the medication they otherwise couldn’t afford. However,...
Judging Melanoma Thickness: Comparison of Dermatologists and Machine-Learning Algorithm
Assessing the thickness of melanoma is difficult—whether done by an experienced dermatologist or a well-trained machine-learning algorithm. A study published by Polesie et al in the Journal of the European Academy of Dermatology and Venereology showed that an algorithm and a group of approximately...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Two Early-Career Cancer Researchers From Africa Aim to Make a Difference and Never Give Up
In countries with a high income, research in oncology is sponsored by funding agencies and industry, which has meaningfully improved survival outcomes of patients with cancer. In contrast, the African continent is disadvantaged in all aspects of human development, particularly in the fields of...
Use of Menopausal Hormone Therapy and Breast Cancer Mortality
Although aromatase inhibitors are effective in reducing estrogen levels and the risk of cancer recurrence in women diagnosed with hormone receptor–positive breast cancer, they can also cause myriad side effects, including genitourinary problems associated with menopause such as vaginal dryness,...
Living With Hereditary Cancer, Oncologist Mark A. Lewis, MD, Shares His Experiences on Social Media to Assist Others
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, FACP, spoke with Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain Healthcare, Murray, Utah, and Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a social media...
Caregivers for Patients With Multiple Myeloma Face Mental Health Challenges
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published by O’Donnell in Blood Advances. Although medical professionals have long acknowledged the toll a serious or terminal diagnosis can have...
Affirming Health Equity: A Model for Integrative Health Care
Guest Editor’s Note: Despite the increasing use of complementary modalities that include mind-body therapies and natural products, significant disparities exist in integrative health care. Contributing factors include access to care and affordability. In this installment of The ASCO Post’s...
For Medicaid-Insured Patients With Cancer, Health Insurance Does Not Always Mean Health-Care Access
Although there has been a significant increase in the number of U.S. residents insured through Medicaid since the Patient Protection and Affordable Care Act was signed into law in March 2010, the ability of Medicaid-insured patients to access cancer care services has not been well understood. In a...
Study Examines Quality-of-Life Outcomes Among Patients Participating in Phase III Randomized Trials of Cancer Drugs
In an analysis that evaluated the outcomes of anticancer drug studies in the advanced disease setting with regard to patient quality of life (QOL), improved QOL outcomes were associated with improved overall survival but not with improved progression-free survival. Almost half of the studies that...
Deciphering the Elusive Origin and Pathways of Brain Metastases
The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from clinical trials of systemic therapies. However, the emergence of molecular targeted therapies has allowed a new treatment approach in patients ...
Addition of Atezolizumab to Neoadjuvant Pertuzumab/Trastuzumab and Docetaxel in HER2-Positive Early Breast Cancer
In the Korean phase II Neo-PATH trial reported in JAMA Oncology, Ahn et al found that neoadjuvant treatment with atezolizumab, pertuzumab/trastuzumab, and docetaxel produced a pathologic complete response in 61% of patients with HER2-positive stage II/III breast cancer treated with the regimen....
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
On July 13, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, adjuvanted, for the prevention of COVID-19 caused by SARS–CoV-2 in individuals aged 18 years and older. “Authorizing an additional COVID-19 vaccine expands the...
Study Reveals Cancer Screening Decreased Worldwide During Height of COVID-19 Pandemic
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal, and cervical cancers during the early phase of the COVID-19 pandemic. The findings of the study,...
Do Bone Marrow Biopsies Aid in Response Assessment for Patients With Follicular Lymphoma?
In a pooled analysis of patients with follicular lymphoma treated in National Clinical Trials Network trials reported in the Journal of Clinical Oncology, Rutherford et al found evidence that bone marrow biopsies can be avoided in response assessment. The investigators stated, “Bone marrow biopsies ...
Immune Checkpoint Inhibitors for Solid Tumors in Kidney Transplant Recipients With Maintained Immunosuppression
In an Australian phase I study reported in The Lancet Oncology, Carroll et al found that maintaining baseline immunosuppression in kidney transplant recipients receiving immune checkpoint inhibitor treatment for advanced solid tumors did not appear to increase the risk of irretrievable allograft...
Expert Point of View: Madhav V. Dhodapkar, MBBS
“BCMA-targeting bispecific antibodies work, showing impressive single-agent activity in heavily pretreated multiple myeloma. This class of agents is likely to become an important component of future antimyeloma therapies, but we must learn how to optimally use them,” said Madhav V. Dhodapkar,...
Responses to Teclistamab Reported in Early-Phase Trial of Highly Refractory Multiple Myeloma
In patients with multiple myeloma exposed or refractory to three standard therapies, treatment with the bispecific antibody teclistamab produced strong and durable responses in the phase I/II MajesTEC-1 study.1 The results of weekly subcutaneous dosing of teclistamab in 165 patients were presented...
Poziotinib Shows Activity in EGFR Exon 20–Mutant NSCLC, With Efficacy Dependent on Insertion Location
A phase II clinical trial of poziotinib for patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 mutations found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may ...
New Gene-Profiling Technology Reveals Potential Melanoma Biomarkers
Diagnosing melanoma clinically and under the microscope can be complicated by the presence of melanocytic nevi, otherwise known as birthmarks or moles that are noncancerous. The development of melanoma is a multistep process, where melanocytes mutate and proliferate. Properly identifying melanoma...
CLN-081 Shows Selective Activity in NSCLC With EGFR Exon 20 Insertions
CLN-081, a novel agent targeted to non–small cell lung cancer (NSCLC) cells harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations—ie, the addition of nucleotide base pairs in exon 20 of the EGFR gene, a known oncogenic driver event—holds promise, according to the results of...
EAU22: Trial Shows New Imaging Technology May Be Less Accurate Than MRI in Detecting Prostate Cancer
A team of researchers in Australia and New Zealand reported that magnetic resonance imaging (MRI) scans may be able to detect prostate cancer more accurately than the newer, prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scanning technique. The...
EAU22: ctDNA May Help to Predict Response to Atezolizumab in Patients With Bladder Cancer
Researchers who treated a group of patients with bladder cancer with the immunotherapy atezolizumab after they had undergone surgery have found that patients whose blood contained circulating tumor DNA (ctDNA) responded very well to the treatment. The study was presented at the European Association ...
Risk of Oropharyngeal Cancer After a Positive HPV16-E6 Serology Test
In an analysis from the Human Papillomavirus Cancer Cohort Consortium (HPVC3) reported in the Journal of Clinical Oncology, Robbins et al found substantial risks of oropharyngeal cancer over time among persons, particularly males, with positive results on human papillomavirus (HPV) 16-E6 serologic...
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
In a phase II study reported in The Lancet Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that mosunetuzumab—a CD20 × CD3 T-cell–engaging bispecific antibody that redirects T cells to eliminate malignant B cells—produced a high rate of complete response in patients with relapsed or...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
ASCO Guideline Update for Systemic Melanoma Therapy Addresses New Treatment Option for Uveal Melanoma
A rapid update to the ASCO guideline on systemic therapy for melanoma adds a new recommendation for the treatment of patients with metastatic uveal melanoma.1 The update follows the January 2022 U.S. Food and Drug Administration (FDA) approval of tebentafusp-tebn for patients with previously...
ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases
Rapid developments over the past decade in the treatment of patients with advanced HER2-positive breast cancer may lead to better outcomes and improved quality of life for patients with brain metastases, according to findings incorporated into a new ASCO guideline update.1 “The difference this...
Expert Point of View: Marianne E. Pavel, MD
Based on the final results of ECOG-ACRIN E2211, invited discussant Marianne E. Pavel, MD, of Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, concluded: “Capecitabine/temozolomide is a preferred regimen…, but temozolomide can still be an option in patients who do not tolerate...
Shaping the Future of Cancer Care: The Value of Managing Aggregated Data From Patients’ Online Communities
In 2021, more than 1.9 million people in the United States were estimated to be diagnosed with cancer, and that number continues to increase yearly. Medical research is critical in prolonging survival and improving the quantity and quality of life of patients. Cancer research is one of the most...
Circulating Tumor DNA–Guided Approach to Treating Stage II Colon Cancer
The use of postoperative circulating tumor DNA (ctDNA) in stage II colon cancer spared many patients the need for adjuvant chemotherapy without compromising recurrence-free survival, according to the phase II DYNAMIC study.1 “The strategy of using ctDNA results to inform treatment almost halved...
Dana-Farber Cancer Institute and L’Institut Servier, of Gustave Roussy, Sign an Oncology Cooperation Agreement
L’Institut Servier, Gustave Roussy, in Villejuif, France, and Dana-Farber Cancer Institute, Boston, have signed a cooperation agreement to foster exchange and develop bilateral collaboration among researchers from these two renowned oncology centers. The 2-year agreement includes the organization...
Cleveland Clinic Appoints Alex A. Adjei, MD, PhD, as Chair of Taussig Cancer Institute
Alex A. Adjei, MD, PhD, is the new Chair of Cleveland Clinic Taussig Cancer Institute. Previously, he served as Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Adjei also oversaw ...
Death and Clinical Trials in the Plague Years
“Everybody knows that pestilences have a way of recurring in the world; yet somehow, we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise.” —Albert Camus, The...
ASCO 2022: Plenary Presentation in Colorectal Cancer
In this episode, we continue to highlight research presented at the 2022 ASCO Annual Meeting. We’ll first hear a discussion between two researchers on Plenary Abstract LBA1, which may establish a standard first-line combination regimen for patients with RAS wild-type and left-sided metastatic...
Phase III Trial Reports Quizartinib Doubles Overall Survival in FLT3-ITD–Positive AML
A new treatment option has doubled overall survival for a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to data presented during the Presidential Symposium at the European Hematology Association (EHA) 2022 Congress in Vienna.1 Findings from the phase III...
Intermittent FOLFIRI Plus Panitumumab Proves More Effective, Less Toxic Than Continuous Treatment in Metastatic Colorectal Cancer
In patients with RAS/BRAF wild-type metastatic colorectal cancer, FOLFIRI (fluorouracil, leucovorin, irinotecan) plus panitumumab can be given intermittently rather than continuously, without compromising outcomes, according to the results of the IMPROVE study presented at the 2022 ASCO Annual...
Addition of Atezolizumab to Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Breast Cancer: IMpassion050
As reported in the Journal of Clinical Oncology by Jens Huober, MD, and colleagues, the phase III IMpassion050 trial showed no significant improvement in pathologic complete response rate with the addition of atezolizumab to neoadjuvant pertuzumab/trastuzumab and chemotherapy in patients with...
Physician Adenoma Detection Rates and Risk of Postcolonoscopy Colorectal Cancer: Is There a Correlation?
In a retrospective cohort study reported in JAMA, Schottinger et al found that patients treated by physicians with higher adenoma detection rates on colonoscopies negative for cancer had a lower risk of postcolonoscopy colorectal cancer and death from colorectal cancer. Study Details The study...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
